BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a hold rating to a strong-buy rating in a report published on Saturday.

Several other research analysts have also recently weighed in on BCRX. Wedbush decreased their target price on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. HC Wainwright reissued a “buy” rating and issued a $32.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Royal Bank Of Canada cut their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Finally, JPMorgan Chase & Co. started coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a “neutral” rating and a $12.00 price objective on the stock. Eight equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $20.60.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX opened at $9.84 on Friday. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.22. The firm has a market capitalization of $2.50 billion, a PE ratio of -6.56 and a beta of 0.55. The company’s 50 day simple moving average is $9.36 and its 200 day simple moving average is $8.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The firm had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The firm’s revenue for the quarter was up 33.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.15 earnings per share. Sell-side analysts anticipate that BioCryst Pharmaceuticals will post -2.44 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of BioCryst Pharmaceuticals in the second quarter worth approximately $238,930,000. RA Capital Management L.P. purchased a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at approximately $123,452,000. Deerfield Management Company L.P. boosted its stake in BioCryst Pharmaceuticals by 159.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after purchasing an additional 7,477,000 shares during the period. Janus Henderson Group PLC boosted its stake in BioCryst Pharmaceuticals by 7,807.2% in the 4th quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock worth $57,791,000 after purchasing an additional 7,310,745 shares during the period. Finally, Perceptive Advisors LLC grew its position in BioCryst Pharmaceuticals by 135.1% during the 1st quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock worth $70,772,000 after purchasing an additional 4,271,504 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.